EUROPEAN COMMISSION APPROVES REVISION OF THERAPEUTIC INDICATION FOR REBIF

Serono has announced that the European Commission has approved an update of the Summary of Product Characteristics (SmPC) of Rebif (interferon beta-1a), in order to align it with current medical practice. Throughout the European Union, Rebif can now be prescribed after the diagnosis of multiple sclerosis (MS) has been confirmed based on one attack and subsequent positive magnetic resonance imaging (MRI) scans.

PipelineReview (http://www.pipelinereview.com/joomla/content/view/5064/101/)